Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia
Key facts
- Who runs it
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 4
- Started
- Dec 2013
- Ended
- Apr 2024
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Travasol (amino acid injection)
- Insulin
- Record updated
- 8 October 2026
- Why it stopped
- organisational problems
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- American Society of Anesthesiologists class<3
- age>18 years
- colorectal surgery for non-metastatic colorectal adenocarcinoma including right and left hemicolectomy, transverse, subtotal and total colectomy sigmoid and low anterior resection
- ability to give informed consent
Who cannot take part
- significant cardiorespiratory, hepatic, renal and neurological disease
- musculoskeletal or neuromuscular disease
- history of severe sciatica, back surgery or other conditions which contraindicate the use of epidural catheters
- confirmed diagnosis of diabetes mellitus or a HbA1c>6.0%
- ingestion of drugs known to affect protein, glucose and lipid metabolism (e.g. steroids)
- severe anemia (hemoglobin<10 g/dL
- BMI>30 Kg/meter squared
- pregnancy
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
The 3 groups in the trial
- Insulin, Travasol (35%) postopTreatment being tested
Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid supplementation) given from start of surgery to 6 hours after, at an amount of 35% of patient's energy expenditure as measured before surgery, .
Treatment: Travasol (amino acid injection) and Insulin
- Insulin, Travasol (20%) postopTreatment being tested
Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid infusion), given from start of surgery to 6 hours after, at an amount of 20% of patient's energy expenditure as measured before surgery.
Treatment: Travasol (amino acid injection) and Insulin
- Insulin, no protein after surgeryPlacebo, for comparison
Insulin (hyperinsulinemic-normoglycemic clamp, an insulin infusion between 2 and 5 microunits/kg with glucose at a variable rated titrated to maintain normoglycemia, blood glucose 4-6 mmol/L) with no protein supplementation from start of surgery to 6 hours after.
Treatment: Insulin
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Perioperative glycaemic control for people with diabetes undergoing surgery.The Cochrane database of systematic reviews, 2023
- Record updated
- 8 October 2026